BrightPath to Update the Pre-clinical Data of BP1210 at SITC 2021

BrightPath Biotherapeutics (TSE Mothers 4954), a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutics, today announced that pre-clinical data on BP1210, anti-TIM-3 antibody, will be presented at the Society for Immunotherapy of Cancer Annual Meeting (SITC 2021, November 14-16, Washington, D.C). Summary of the abstract and the electronic poster will be posted on the website of BrightPath at after SITC 2021 is held.

BP1210

Research title: Novel biparatopic TIM-3 antibody effectively blocks multiple inherent ligands and activates anti-tumor immunity

Date & Time: 7 a.m.-8 p.m. EST on Friday, November 12, 2021

Poster Session: Checkpoint Blockade Therapy

Abstract number: 235